# US 2026/0097054 A1 · Arginine silicate inositol for improving cognitive function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097054 A1
- Document ID: US20260097054A1
- Status: Published application
- Kind: A1
- Application number: 19/324,850
- Filed: 2025-09-10
- Published: 2026-04-09
- Earliest claimed: 2015-06-30
- Assignees: Nutrition21, LLC
- Applicants: Nutrition21, LLC
- Inventors: James R. Komorowski
- Web page: https://patentgrep.com/patent/US20260097054A1

## CPC

- A61K 31/695: Silicon compounds
- A61B 5/4088: {Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to the use of inositol-stabilized arginine (“ASI”) for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and/or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and/or attention span in humans. Some embodiments include the use of ASI for treating and/or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder (“ADHD”), and other learning disabilities.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for improving mood in a subject in need thereof, the method comprising administering to the subject an effective amount of inositol-stabilized arginine silicate.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is a healthy subject.

### Claim 23 (depends on 21)

The method of claim 21, wherein the subject is an adult subject.

### Claim 24 (depends on 21)

The method of claim 21, wherein the subject is a male subject.

### Claim 25 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is administered orally.

### Claim 26 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is administered to the subject once per day.

### Claim 27 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is from about 0.5 g to about 5 g per day.

### Claim 28 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is from about 1 g to about 3 g per day.

### Claim 29 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is about 1.5 g per day.

### Claim 30 (depends on 21)

The method of claim 21, further comprising increasing nitric oxide production.

### Claim 31

A method of improving energy in a subject in need thereof, the method comprising administering to the subject an effective amount of inositol-stabilized arginine silicate.

### Claim 32 (depends on 31)

The method of claim 31, wherein the subject is a healthy subject.

### Claim 33 (depends on 31)

The method of claim 31, wherein the subject is an adult subject.

### Claim 34 (depends on 31)

The method of claim 31, wherein the subject is a male subject.

### Claim 35 (depends on 31)

The method of claim 31, wherein the effective amount of inositol-stabilized arginine silicate is administered orally.

### Claim 36 (depends on 31)

The method of claim 31, wherein the effective amount of inositol-stabilized arginine silicate is administered to the subject once per day.

### Claim 37 (depends on 31)

The method of claim 31, wherein the effective amount of inositol-stabilized arginine silicate is from about 0.5 g to about 5 g per day.

### Claim 38 (depends on 31)

The method of claim 31, wherein the effective amount of inositol-stabilized arginine silicate is from about 1 g to about 3 g per day.

### Claim 39 (depends on 21)

The method of claim 21, wherein the effective amount of inositol-stabilized arginine silicate is about 1.5 g per day.
